Urgent Care Chiropractic - Auburn | |
1340 M St Se Ste C, Auburn, WA 98002-6755 | |
(253) 929-8398 | |
Not Available |
Full Name | Urgent Care Chiropractic - Auburn |
---|---|
Type | Facility |
Speciality | Clinic/center |
Location | 1340 M St Se Ste C, Auburn, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558843862 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
111N00000X | Chiropractor | (Washington) | Secondary |
261Q00000X | Clinic/center | (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Urgent Care Chiropractic - Auburn 3910 196th St Sw Ste E, Lynnwood, WA 98036-5770 Ph: (253) 929-8398 | Urgent Care Chiropractic - Auburn 1340 M St Se Ste C, Auburn, WA 98002-6755 Ph: (253) 929-8398 |
News Archive
A study by researchers at University of Colorado Cancer Center and Oregon Health & Science University published today in the Journal of the American Medical Association Network shows that breast cancers diagnosed in young women within 10 years of giving birth are more likely to metastasize, and thus more likely to cause death, than breast cancers in young women who gave birth less recently or not at all.
A new study in mice suggests that consuming the chemical compounds found in thermally abused cooking oil may trigger genetic changes that promote the progression of late-stage breast cancer.
U.S. Secretary of State Hillary Clinton "expressed concern" over Uganda's increasing number of HIV infections on a visit to the country last week, part of an 11-day trip to eight African nations, Uganda's New Vision reports (Mukasa, 8/4).
Kaiser Permanente research published today in the American Journal of Preventive Medicine found if patients with hypertension taking prescribed medications experience unusually low blood pressures - systolic blood pressure under 110mmHg - they are twice as likely to experience a fall or faint as patients whose treated blood pressure remains 110mmHg and above.
In statehouses around the country, some of the nation's biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.
› Verified 6 days ago